KR101333861B1 - Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체 - Google Patents

Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체 Download PDF

Info

Publication number
KR101333861B1
KR101333861B1 KR1020077029797A KR20077029797A KR101333861B1 KR 101333861 B1 KR101333861 B1 KR 101333861B1 KR 1020077029797 A KR1020077029797 A KR 1020077029797A KR 20077029797 A KR20077029797 A KR 20077029797A KR 101333861 B1 KR101333861 B1 KR 101333861B1
Authority
KR
South Korea
Prior art keywords
chloro
acetic acid
indol
trioxospyro
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077029797A
Other languages
English (en)
Korean (ko)
Other versions
KR20080031191A (ko
Inventor
매티아스 슈와츠
에릭 세빌
크리스토프 클레바
세드릭 멀롯
데니스 쳐치
패트릭 페이지
쟈께린 에이. 마크릿시에
존 프레드릭 애써럴
스테파노 크로시그나니
도리스 푸포윅쯔
Original Assignee
메르크 세로노 에스. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 세로노 에스. 에이. filed Critical 메르크 세로노 에스. 에이.
Publication of KR20080031191A publication Critical patent/KR20080031191A/ko
Application granted granted Critical
Publication of KR101333861B1 publication Critical patent/KR101333861B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020077029797A 2005-05-24 2006-05-23 Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체 Expired - Fee Related KR101333861B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05104428.7 2005-05-24
EP05104428 2005-05-24
US68863105P 2005-06-08 2005-06-08
US60/688,631 2005-06-08
PCT/EP2006/062545 WO2006125784A1 (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as crth2 modulators

Publications (2)

Publication Number Publication Date
KR20080031191A KR20080031191A (ko) 2008-04-08
KR101333861B1 true KR101333861B1 (ko) 2013-11-28

Family

ID=35478408

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077029797A Expired - Fee Related KR101333861B1 (ko) 2005-05-24 2006-05-23 Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체

Country Status (20)

Country Link
US (1) US8236963B2 (enExample)
EP (1) EP1891075B1 (enExample)
JP (1) JP5567268B2 (enExample)
KR (1) KR101333861B1 (enExample)
CN (1) CN101300259B (enExample)
AR (1) AR055959A1 (enExample)
AT (1) ATE529429T1 (enExample)
AU (1) AU2006251138C1 (enExample)
BR (1) BRPI0610209A2 (enExample)
CA (1) CA2602965C (enExample)
DK (1) DK1891075T3 (enExample)
ES (1) ES2375614T3 (enExample)
MX (1) MX2007014256A (enExample)
NZ (1) NZ562772A (enExample)
PL (1) PL1891075T3 (enExample)
PT (1) PT1891075E (enExample)
RU (1) RU2478639C2 (enExample)
UA (1) UA90145C2 (enExample)
WO (1) WO2006125784A1 (enExample)
ZA (1) ZA200709819B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101411820B1 (ko) 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
WO2011006936A1 (en) 2009-07-15 2011-01-20 Merck Serono S.A. Tricyclic indole-derived spiro derivatives as crth2 modulators
JP2013510860A (ja) 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
PL2558447T3 (pl) 2010-03-22 2015-03-31 Idorsia Pharmaceuticals Ltd Pochodne 3-(heteroaryloamino)-1,2,3,4-tetrahydro-9h-karbazolu i ich zastosowanie jako modulatorów receptora prostaglandyny D2
TWI535723B (zh) 2010-11-12 2016-06-01 密西根大學董事會 螺－吲哚酮ｍｄｍ２拮抗劑
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US9096595B2 (en) 2011-04-14 2015-08-04 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
SG194873A1 (en) 2011-05-11 2013-12-30 Sanofi Sa Spiro-oxindole mdm2 antagonists
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CN103554118B (zh) * 2013-10-15 2015-08-19 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物及其应用
CN103554119B (zh) * 2013-10-15 2015-09-16 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物的制备方法
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
HUE039614T2 (hu) 2014-03-17 2019-01-28 Idorsia Pharmaceuticals Ltd Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk
KR20160133536A (ko) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도
JP2018531213A (ja) 2015-03-13 2018-10-25 フォーマ セラピューティクス，インコーポレイテッド Ｈｄａｃ８阻害剤としてのアルファ−シンナミド化合物及び組成物
TR201909160T4 (tr) 2015-07-15 2019-07-22 Hoffmann La Roche Metabotropik glutamat reseptörü modülatörleri olarak etinil türevleri.
MX379014B (es) 2015-09-15 2025-03-10 Idorsia Pharmaceuticals Ltd Formas cristalinas.
RU2631856C1 (ru) * 2016-05-04 2017-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ получения аммонийных солей 3-амино-8-гидрокси-1,6-диоксо-4-циано-2,7-диазаспиро[4.4]нон-3-ен-2-идов
JP6936305B2 (ja) 2016-07-18 2021-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エチニル誘導体
CN109384794B (zh) * 2017-08-08 2020-06-19 沈阳药科大学 质子酸催化的一类四环吲哚骨架的合成方法
CN109369658B (zh) * 2017-08-08 2020-01-31 沈阳药科大学 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法
CN109384787B (zh) * 2017-08-08 2021-04-16 沈阳药科大学 一种一价银催化的氢化吡啶螺二氢吲哚环的合成方法
KR101857408B1 (ko) 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
US20230065740A1 (en) 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386100A (en) 1981-05-12 1983-05-31 Imperial Chemical Industries Plc Spiro [imidazolidine 4,3'-indoline]2,2',5-triones, compositions and use
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE53102B1 (en) * 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
ID30176A (id) * 1999-03-12 2001-11-08 Boehringer Ingelheim Pharma Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1556047A4 (en) 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
ATE327977T1 (de) 2002-10-21 2006-06-15 Warner Lambert Co Tetrahydrochinolin-derivate als crth2 antagonisten
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US20050038070A1 (en) 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
CA2563707A1 (en) 2004-04-20 2005-11-03 Pfizer Inc. Method of treating neuropathic pain using a crth2 receptor antagonsit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386100A (en) 1981-05-12 1983-05-31 Imperial Chemical Industries Plc Spiro [imidazolidine 4,3'-indoline]2,2',5-triones, compositions and use
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban

Also Published As

Publication number Publication date
JP5567268B2 (ja) 2014-08-06
EP1891075A1 (en) 2008-02-27
CN101300259B (zh) 2013-08-28
US8236963B2 (en) 2012-08-07
US20090318486A1 (en) 2009-12-24
AU2006251138A1 (en) 2006-11-30
JP2008542238A (ja) 2008-11-27
AR055959A1 (es) 2007-09-12
CA2602965C (en) 2013-12-31
RU2478639C2 (ru) 2013-04-10
MX2007014256A (es) 2008-03-26
PT1891075E (pt) 2011-11-10
ATE529429T1 (de) 2011-11-15
AU2006251138C1 (en) 2013-08-29
ZA200709819B (en) 2009-09-30
RU2007147430A (ru) 2009-06-27
DK1891075T3 (da) 2011-12-19
PL1891075T3 (pl) 2011-12-30
UA90145C2 (ru) 2010-04-12
NZ562772A (en) 2010-01-29
BRPI0610209A2 (pt) 2010-06-01
CN101300259A (zh) 2008-11-05
AU2006251138B2 (en) 2012-08-09
ES2375614T3 (es) 2012-03-02
CA2602965A1 (en) 2006-11-30
EP1891075B1 (en) 2011-10-19
WO2006125784A1 (en) 2006-11-30
KR20080031191A (ko) 2008-04-08

Similar Documents

Publication Publication Date Title
KR101333861B1 (ko) Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체
KR101331771B1 (ko) 베타 3 아드레날린성 수용체 효능제로서의 하이드록시메틸 피롤리딘
US11337970B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
TWI609018B (zh) 新穎雙環衍生物
CN105517999B (zh) Ido抑制剂
JP6177456B2 (ja) 二環式縮合ヘテロアリールまたはアリール化合物およびｉｒａｋ４阻害剤としてのそれらの使用
KR102510588B1 (ko) 카텝신 c의 스피로사이클릭 억제제
JP5249344B2 (ja) ヘテロ環の３位が置換されたインドール誘導体およびその使用
KR20060006057A (ko) 카나비노이드 수용체 리간드 및 그의 용도
JP2015147792A (ja) β−セクレターゼ阻害剤
JP2021530442A (ja) 縮合三環系複素環化合物およびその治療上の使用
HK1121146A1 (en) Tricyclic spiro derivatives as crth2 modulators
HK1121146B (en) Tricyclic spiro derivatives as crth2 modulators
WO2013001498A1 (en) Amidoalkylpiperazinyl derivatives for the treatment of central nervous system diseases
WO2006036031A1 (ja) 縮合フラン誘導体およびその用途
CN100522161C (zh) 作为大麻素cb1受体的激动剂的(吲哚-3-基)-杂环衍生物
CN119855589A (zh) 杂环pad4抑制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20161122

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20161122